Drugmaker Mylan has become a target of criticism in response to claims that it’s engaging in sneaky EpiPen maneuvers to shield its profits.
Drugmaker Mylan has become a target of criticism in response to claims that it’s engaging in sneaky EpiPen maneuvers to shield its profits.